ClinicalTrials.gg
WithdrawnNCT06046274Updated Apr 30, 2024

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

A Phase 2 interventional study of Pembrolizumab and Acasunlimab in Advanced Endometrial Cancer, sponsored by Genmab. Withdrawn at 29 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Enrollment challenged by availability of other treatment options

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of — 35 open to participants now, 59 under way, 17 of them phase 3. Endometrial Neoplasms · Korea, Republic of.

Enrollment
76th of 76
0 · median 287
Started
2023
with 6 others
Phase 2
19 of 85
8 open now
Registered
60th of 85
by date

Among the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, this one is the 76th largest by enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2023, is one of 19 in phase 2, and was the 60th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

35 of the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb). The main questions the study aims to answer are:

  • How well acasunlimab in combination with pembrolizumab works against endometrial cancer
  • What are the potential side effects participants may experience when they are treated with acasunlimab in combination with pembrolizumab

Participants will receive both acasunlimab and pembrolizumab. All participants will receive active drug; no one will receive placebo. participants will participate in 1 of 2 cohorts. A participant will receive study treatment up to a maximum of 24 months. The study duration (including screening, treatment, and follow-up) for each participant will be about 39 months.

Read the detailed description

This is an open-label multicenter study in participants with advanced (unresectable and/or metastatic) endometrial cancer to evaluate the safety and clinical activity of acasunlimab (GEN1046) in combination with immunotherapy.

The trial consists of two cohorts:

  • Cohort A (cohort closed)
  • Cohort B

The study will enroll approximately 80 participants in Cohort A and B (approximately 40 participants in each cohort).

03

Conditions studied

  • Advanced Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of advanced (unresectable, recurrent, and/or ) endometrial carcinoma that is incurable and for which prior standard treatment has failed.
  • Prior to Cycle 1 Day 1 (C1D1), documentation of tumor dMMR/MSI-H status must be available based on local testing.
  • Must have progressed on or after at least 1 (but no more than 2) prior line(s) of a systemic chemotherapy regimen for unresectable and/or metastatic endometrial cancer of which at least 1 regimen of platinum-based treatment unless participant is ineligible for or intolerant to platinum.
  • Cohort A only: Must be treatment naive for CPIs including or PD-L1 inhibitors and other immune CPIs (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT).
  • Cohort B only: Must have received and progressed on or after prior treatment with a PD-1/PD-L1 inhibitor alone or in combination. Moreover, the participant's duration of CPI containing treatment and best overall response (BOR) is known, and participant has received a minimum of 2 cycles of CPI.

Exclusion criteria

Exclusion Criteria:

  • Histological diagnosis of carcinosarcoma, malignant mixed Műllerian tumor, endometrial leiomyosarcoma, or endometrial stromal sarcomas.
  • Ongoing or active infection requiring intravenous treatment with anti-infective therapy, or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
  • Any prior treatment with any type of antitumor vaccine, or autologous cell immunotherapy.
  • Radiotherapy within 14 days prior to first dose of acasunlimab. Note: palliative radiotherapy will be allowed for local pain control under certain conditions.
  • Treatment with an anticancer agent, including vaccines within 28 days before or 5 times t1/2, whichever is shorter, prior to the planned first dose of trial treatment or is currently enrolled in an interventional trial.
  • Prior treatment with live, attenuated vaccines within 30 days prior to initiation of trial treatment.
  • Received granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support within 4 weeks before the planned first dose of trial treatment.
  • Cohort A only: Prior exposure to immune CPIs other than /anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40)
  • Cohort B only:

    • Known history of Grade 3 or higher immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy treatment
    • Exposure to any of the following prior therapies/treatments within the specified timeframes:
    • Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40)
    • PD-1/PD-L1 antibody within 28 days before the planned first dose of trial treatment

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort A: pembrolizumab + acasunlimab

    Pembrolizumab will be administered in combination with acasunlimab as second-line (2L) or third-line (3L) therapy for dMMR/MSI-H in checkpoint inhibitor (CPI) naïve participants.

    Biological: Pembrolizumab · Biological: Acasunlimab

  • Experimental
    Cohort B: pembrolizumab + acasunlimab

    Pembrolizumab will be administered in combination with acasunlimab as 2L or 3L therapy for mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) participants who had prior exposure to programmed cell death protein/ programmed death ligand 1 (PD-1/PD-L1) inhibitors.

    Biological: Pembrolizumab · Biological: Acasunlimab

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab intravenous (IV) infusion

  • BiologicalAcasunlimab

    Acasunlimab IV infusion

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed response of partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.

    Time frame: Up to 4 years

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined for responders as the time from initial onset of response to first progression event, defined as radiographic progression or death as per RECIST v1.1.

    Time frame: Up to 4 years

  2. Time to Response (TTR)

    TTR is defined as the time from first infusion of trial treatment to onset of response as per RECIST v1.1.

    Time frame: Up to 4 years

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with a confirmed response of PR or CR or stable disease (SD) according to RECIST v1.1.

    Time frame: Up to 4 years

  4. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and as Per Severity

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product as per CTCAE V5.0. TEAE is defined as an AE occurring or worsening between the first dose of study drug and 30 days after the last dose received.

    Time frame: From first dose date up to 90 days after the study treatment

07

Study locations

29 sites
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
  • Rudgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Cliniques Universitaires Saint-Luc
    Brussel, 1200, Belgium
  • Grand Hospital de Charleroi
    Charleroi, Belgium
  • Universitair Ziekenhuis Ghent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Aalborg University Hospital
    Aalborg, 9100, Denmark
  • Rigshospitalet
    Copenhagen, Denmark
  • Odense Universitetshospital
    Odense, Denmark
  • AOU Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, Italy
  • IRCCS Istituto Europeo di Oncologia IEO
    Milano, Italy
  • Fondazione G. Pascale
    Napoli, Italy
  • IRCCS Policlinico Universitario Agostino Gemelli
    Roma, Italy
  • Ospedale Mauriziano Umberto I
    Torino, Italy
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
  • National Cancer Center Korea
    Goyang-si, Korea, Republic of
  • Pusan National University
    Pusan, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Severance Hospital, Yonsei University Health System|Division of Infectious Diseases
    Seoul, Korea, Republic of
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • ICO Girona
    Girona, Spain
  • Clínica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Fundacion Jiménez Díaz
    Madrid, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2023; primary completion for Apr 2028, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartEst.
Oct 1, 2023
Primary completionEst.
Apr 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046274
Lead sponsor
Genmab
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Apr 30, 2024

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acasunlimab

Start the discussion